Taken together with previous studies demonstrating the ability of A2AR blockade to reduce Tau hyperphosphorylation and associated cognitive decline (Laurent et al., 2016; Zhao et al., 2017), these data support that A2AR signaling is a target of interest in AD. Here, MAPT is linked to Alzheimer disease.